S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:MACK

Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

$4.22
+0.02 (+0.48%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.18
▼
$4.27
50-Day Range
$4.16
▼
$6.24
52-Week Range
$3.66
▼
$7.41
Volume
12,951 shs
Average Volume
59,058 shs
Market Capitalization
$56.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Merrimack Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.25mentions of Merrimack Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$188,276 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

961st out of 1,135 stocks

Pharmaceutical Preparations Industry

478th out of 557 stocks

See Top Rated MarketRank™ Stocks Here
MACK stock logo

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals Trading Up 0.5 %

NASDAQ:MACK traded up $0.02 on Friday, reaching $4.22. The company had a trading volume of 12,951 shares, compared to its average volume of 59,058. The company's fifty day moving average is $5.39 and its 200 day moving average is $5.72. Merrimack Pharmaceuticals has a 52-week low of $3.66 and a 52-week high of $7.41.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Merrimack Pharmaceuticals in a research report on Tuesday, August 9th. They set a "sell" rating on the stock.

Insider Activity at Merrimack Pharmaceuticals

In related news, Director Noah G. Levy purchased 20,938 shares of the stock in a transaction that occurred on Tuesday, June 14th. The stock was acquired at an average cost of $5.17 per share, with a total value of $108,249.46. Following the transaction, the director now owns 1,010,515 shares of the company's stock, valued at approximately $5,224,362.55. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders purchased 35,478 shares of company stock valued at $188,276. 25.80% of the stock is owned by insiders.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

August 8, 2022 | seekingalpha.com
Merrimack Pharmaceuticals: Out For Now
August 4, 2022 | americanbankingnews.com
Merrimack Pharmaceuticals (NASDAQ:MACK) Earns Sell Rating from Analysts at StockNews.com
August 4, 2022 | marketwatch.com
Merrimack Pharma Shares Tumble Premarket After Ipsen's Onivyde Update >MACK
August 3, 2022 | nasdaq.com
Merrimack: Ipsen's Phase 3 Trial Of Onivyde Fails To Meet Primary Endpoint
August 3, 2022 | finance.yahoo.com
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
July 24, 2022 | americanbankingnews.com
Merrimack Pharmaceuticals (NASDAQ:MACK) Research Coverage Started at StockNews.com
July 22, 2022 | nz.finance.yahoo.com
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032: Visiongain Reports Ltd
July 6, 2022 | finance.yahoo.com
Bullish insiders at Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) loaded up on US$574k of stock earlier this year
May 5, 2022 | seekingalpha.com
Merrimack Pharmaceuticals GAAP EPS of -$0.01
March 16, 2022 | bizjournals.com
This drug manufactured in Lynnwood can help you survive a nuclear blast
March 16, 2022 | bizjournals.com
This Mass. company’s drug can help you survive a nuclear blast
March 9, 2022 | finance.yahoo.com
Merrimack Reports Full Year 2021 Financial Results
March 9, 2022 | seekingalpha.com
Merrimack Pharmaceuticals reports FY results
January 27, 2022 | finance.yahoo.com
Insider Buying: The Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Co-Founder & Independent Director Just Bought 63% More Shares
January 24, 2022 | nasdaq.com
One Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider upped their stake by 43% in the previous year
January 13, 2022 | nasdaq.com
Thursday 1/13 Insider Buying Report: MACK, ASO
January 5, 2022 | markets.businessinsider.com
Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round
December 6, 2021 | finance.yahoo.com
Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
November 4, 2021 | finance.yahoo.com
Merrimack Reports Third Quarter 2021 Financial Results
October 7, 2021 | sg.finance.yahoo.com
Merrimack Pharmaceuticals, Inc. (MACK)
September 6, 2021 | finance.yahoo.com
A Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider increased their holdings by 43% last year
August 5, 2021 | finance.yahoo.com
Merrimack Reports Second Quarter 2021 Financial Results
June 16, 2021 | uk.finance.yahoo.com
MACK Jun 2021 15.000 call
June 8, 2021 | finance.yahoo.com
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth
May 28, 2021 | finance.yahoo.com
180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings
5/10/2019
Today
8/14/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MACK
CUSIP
59032810
CIK
1274792
Web
www.merrimackpharma.com
Phone
617-441-1000
Fax
617-491-1386
Employees
426
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,450,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-14.55%
Return on Assets
-13.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
31.85
Quick Ratio
25.91

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.02 per share
Price / Book
4.14

Miscellaneous

Outstanding Shares
13,410,000
Free Float
9,950,000
Market Cap
$56.59 million
Optionable
Optionable
Beta
1.32

Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2022?

Merrimack Pharmaceuticals' stock was trading at $3.91 on January 1st, 2022. Since then, MACK shares have increased by 7.9% and is now trading at $4.22.
View the best growth stocks for 2022 here.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MACK earnings forecast.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) issued its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.14.

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals's stock reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sepio Capital LP (2.36%), Yakira Capital Management Inc. (0.86%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $4.22.

How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $56.59 million. The biopharmaceutical company earns $-2,450,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Merrimack Pharmaceuticals have?

The company employs 426 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-441-1000, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.